Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

11 Oct 2012

Abstract excerpt

Few therapeutic options exist for the highly aggressive triple negative breast cancers (TNBCs). In this study, we report that a contextual synthetic lethality can be achieved both in vitro and in vivo with combined EGFR and PARP inhibition with lapatinib and ABT-888, respectively. The mechanism involves a transient DNA double strand break repair deficit induced by lapatinib and subsequent activation of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23071597
DOI: 10.1371/journal.pone.0046614

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer CellsPMID 23071597Read ↗

Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer.Semantic proximity Read ↗

The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethalitySemantic proximity Read ↗

Breast Cancer Predisposition Genes and Synthetic Lethality.Semantic proximity Read ↗

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast CancerSemantic proximity Read ↗

Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer CellsSemantic proximity Read ↗

Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependentSemantic proximity Read ↗

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparibSemantic proximity Read ↗

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cellsSemantic proximity Read ↗

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.Semantic proximity Read ↗

Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.Semantic proximity Read ↗

Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Semantic proximity Read ↗

Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.